Anti-CD6 humanized monoclonal antibody itolizumab, halts disease progression and severity of acute respiratory distress syndrome in COVID-19 disease: A case study

Anti-CD6 humanized monoclonal antibody itolizumab, halts disease progression and severity of acute respiratory distress syndrome in COVID-19 disease: A case study

In COVID-19 patients, cytokine release syndrome plays a critical role in disease progression. Itolizumab inhibits T-cell proliferation and differentiation, thereby modulating imminent cytokine storm. Here, we report a case of a 44-year-old male patient with confirmed COVID-19 and oxygen saturation (...

Full description

Bibliographic Details
Main Authors: Hemant P Thacker, Amit Dhekane, Nivedita Wadhwa, Shalaka Patil
Format: Article
Language:English
Published: Jaypee Brothers Medical Publisher 2021-01-01
Series:Indian Journal of Respiratory Care
Subjects:
acute respiratory distress syndrome
cd6
covid-19
cytokine storm
hyperinflammation
itolizumab
Online Access:http://www.ijrc.in/article.asp?issn=2277-9019;year=2021;volume=10;issue=1;spage=112;epage=115;aulast=

Internet

http://www.ijrc.in/article.asp?issn=2277-9019;year=2021;volume=10;issue=1;spage=112;epage=115;aulast=

Similar Items